Skip to main content
  • Home
  •  Dual Antiplatelet Therapy for Acute Stroke and TIA: Current Best Practice and Emerging Strategies

Dual Antiplatelet Therapy for Acute Stroke and TIA: Current Best Practice and Emerging Strategies

Topic:
  • Heart Failure
  • Prevention

Available Credit:

  • 1.00 EBAC

Course Published On:

Course Expiry Date:

Dual Antiplatelet Therapy for Acute Stroke and TIA

Overview

In the days and weeks following a minor stroke or transient ischaemic attack (TIA), patients are at increased risk for a secondary stroke. Secondary strokes are common and are often more disabling and more likely to be fatal than the index event. Patients are at the greatest risk for a secondary stroke in the 30 days following an acute event, with an estimated 5.2% of patients experiencing a recurrent ischaemic stroke in the first 7 days after an index event. Clinical studies have demonstrated that the acute treatment of ischaemic stroke or TIA should include antiplatelet therapy within 24 hours of an index event with dual antiplatelet therapy (DAPT; aspirin + clopidogrel) recommended for 21 days after an event. While the benefit of DAPT for reducing thrombotic risk after a stroke has been established, findings from recent studies suggest that alternative agents and durations of treatment following and acute minor ischaemic stroke or TIA may further reduce the risk of secondary stroke and improve outcomes for patients. Such data also highlight the need for a personalized approach to secondary stroke prevention which takes account of individual risk factors in terms of underlying causation, health status and bleeding risk. Increased awareness among physicians of these recent developments and strategies to assess early stroke risk and use this information to guide the choice of therapy is necessary to implement these findings in clinical practice.

Disclosure

In compliance with EBAC / EACCME guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.

 

The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

 

This programme is supported by an unrestricted educational grant from AstraZeneca. The scientific programme has not been influenced in any way by the sponsor.

Terms & Conditions

Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.

 

This session ‘Dual antiplatelet therapy for acute stroke and TIA: Current best practice and emerging strategies’ is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credits.

 

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

 

Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.

Instructions to Participants

There is no fee for taking part in this online learning activity.

 

Activities are designed to be completed within 60 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.

 

To complete the course and claim certification participants must:

  • Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
  • Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.

Learning Objectives

  • To highlight the continued high unmet need for strategies to prevent stroke or death for patients experiencing acute stroke or TIA
  • To outline the guidelines on the use of dual antiplatelet therapy for patients presenting with acute stroke or TIA
  • To examine recent evidence from clinical trials on novel strategies for improving outcomes for patients presenting with acute stroke or TIA and how these data and insights can be applied in clinical practice

Module

Title

Duration

Speakers

1 Chairperson’s welcome and introduction Pierre Amarenco (Paris University, FR)
2 Secondary prevention following acute minor stroke or TIA: Understanding the ongoing risk Peter Rothwell (University of Oxford, UK)
3 Current best practice: Evidence-based antiplatelet therapy for secondary stroke prevention Pierre Amarenco (Paris University, FR)
4 Evolving role of dual antiplatelet therapy for stroke prevention: Advancing best practice for patients at high risk Clay Johnston (The University of Texas, Austin, US)
5 Clinical decision making for the patient presenting with acute stroke Peter Schellinger (Universitatslinikum Der Ruhr-Universitat Bochum, DE)
6 Faculty discussion: The use of anti-platelet therapy to manage patients following an acute stroke Pierre Amarenco (Paris University, FR) Peter Rothwell (University of Oxford, UK) Clay Johnston (The University of Texas, Austin, US) Peter Schellinger (Universitatslinikum Der Ruhr-Universitat Bochum, DE)
1.

Chairperson’s welcome and introduction

Duration:

Speakers: Pierre Amarenco (Paris University, FR)

2.

Secondary prevention following acute minor stroke or TIA: Understanding the ongoing risk

Duration:

Speakers: Peter Rothwell (University of Oxford, UK)

3.

Current best practice: Evidence-based antiplatelet therapy for secondary stroke prevention

Duration:

Speakers: Pierre Amarenco (Paris University, FR)

4.

Evolving role of dual antiplatelet therapy for stroke prevention: Advancing best practice for patients at high risk

Duration:

Speakers: Clay Johnston (The University of Texas, Austin, US)

5.

Clinical decision making for the patient presenting with acute stroke

Duration:

Speakers: Peter Schellinger (Universitatslinikum Der Ruhr-Universitat Bochum, DE)

Course Director

Pierre Amarenco

Paris University

Pierre Amarenco is Professor of Neurology at Paris University, France.

View full profile

Speaker

Peter Rothwell

University of Oxford

Peter M Rothwell is Founding Director, at the Wolfson Centre for Prevention of Stroke and Dementia, Action Research Professor of Neurology, at the University of Oxford, UK

View full profile

Clay Johnston

Harbor Health, Texas, US

Prof Clay Johnston is Co-Founder and Chief Medical Officer at Harbor Health, Texas, US. 

View full profile

Peter Schellinger

Johannes Wesling Klinikum Minden

Peter D Schellinger is Chairman of the Department of Neurology and Neurogeriatrics at Johannes Wesling Klinikum Minden at the Universitatslinikum Der Ruhr-Universitat Bochum.

View full profile
1.00 EBAC

Related Courses

Medical Options for Advanced HFpEF/HFmrEF Patients: An Expert-Guided Virtual Ward Round
  • 1.00 EBAC

Learning objectives

  • Describe the current limitations of HFmrEF/HFpEF GDMT in advanced patients
  • Select appropriate patients for advanced medical therapy
  • Recall recent trial data for novel therapeutic approaches
  • Use expert guidance to develop an evidence-based approach to managing advanced HFmrEF/HFpEF
See more
Bridging the Gap in Worsening Heart Failure: Evidence-Based Approaches to Optimising Treatment Outcomes
  • 1.25 AMA PRA Credit

Learning objectives

  • To identify high-risk patient features indicative of worsening Heart Failure (HF)
  • Name validated tools for serial prognostic assessment and risk stratification
  • Adopt the use of appropriate assessment tools during patient follow-up
  • Recall rates of recurrent HF events and their associated healthcare costs in worsening HF patients
  • Recall the clinical benefit of emerging treatments targeted to treating worsening HF
  • Initiate available treatment for the tailored management of worsening HF
See more
Cardiac Amyloidosis: Emerging Diagnostic and Treatment Approaches
  • 1.00 EBAC

Learning objectives

  • Understand the nature of amyloidosis and its effects on various organs, particularly the heart
  • Distinguish between light-chain (AL) amyloidosis, wild type TTR amyloidosis and hereditary TTR amyloidosis in terms of their clinical manifestations and their different treatments
  • Recognise the novel challenges of managing heart failure in cardiac amyloidosis, including both medical management and the role of devices
  • Understand the critically important interaction between haematologists and cardiologists in the therapy of AL amyloidosis
  • Develop an understanding of novel therapies currently in clinical trials of TTR and AL amyloidosis
  • Identify their own roles and responsibilities in the management TTR and AL amyloidosis as part of a multidisciplinary team
See more
Advancing Patient Care in Hypertrophic Cardiomyopathy
  • 0.50 AMA PRA Credit

Learning objectives

  • Recall recent trial data for novel disease modifying therapy in HCM
  • Describe the evolving guideline directed approach to managing HCM
  • Develop an expert-led approach to implementing novel therapy in clinical practice
See more
A Race Against Time: Accelerating the Adoption of GDMT in Heart Failure
  • Not accredited

Learning objectives

  • Recall guideline recommendations for the use of NT-proBNP in heart failure
  • Describe current practices in heart failure diagnosis and the impact on treatment outcomes
  • Develop an optimised approach to the timely diagnosis and management of heart failure
See more
An Expert Approach to Cardio-Renal Protection in CKD
  • 2.00 EBAC

Learning objectives

  • Recall clinical evidence and guidelines for the management of CKD patients without diabetes
  • Describe current gaps and barriers in evidence-based management for CKD without diabetes
  • Apply evidence based-management strategies to a case study
  • Use expert-led guidance to develop an optimal management approach to CKD patients without diabetes
See more
Implementing Heart Failure Guidelines with Collaborative Care
  • Not accredited

Learning objectives

  • Appraise new updates in heart failure guideline-directed medical therapy (GDMT)
  • Apply latest guideline recommendations to patient cases
  • Describe barriers preventing early initiation of GDMT
  • Identify the roles of nurses and other healthcare professionals to achieve optimal heart failure therapy
  • Identify the importance of the nurse/cross-functional team
See more
Overcoming the Challenges in Optimising GDMT in HF
  • Not accredited

Learning objectives

  • Appraise the urgency needed in rapid initiation of GDMT to improve HF outcomes.
  • Recognise barriers preventing the use of GDMT in current practice.
  • Identify strategies needed to drive implementation of GDMT in clinical practice.
See more
Hyperkalaemia in Cardiorenal Disease – A Case Based Discussion
  • Not accredited

Learning objectives

  • Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
  • Identify patients who would benefit from anti-hyperkalaemia medications
  • Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
  • Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
  • Summarise current guideline recommendations on the use of potassium binding agents
See more
Examining a Complex Heart Failure Case
  • 1.00 EBAC

Learning objectives

  • Identify individuals likely to have HFpEF from initial presentation
  • Refer suspected individuals for specialist assessment
  • Initiate GDMT for HF as soon as patients are stable 
  • Initiate GDMT in HF regardless of EF and phenotype
  • Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists
See more